191,578 Shares in Ultragenyx Pharmaceutical Inc. $RARE Acquired by Connor Clark & Lunn Investment Management Ltd.

Connor Clark & Lunn Investment Management Ltd. purchased a new stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 191,578 shares of the biopharmaceutical company’s stock, valued at approximately $6,397,000. Connor Clark & Lunn Investment Management Ltd. owned approximately 0.19% of Ultragenyx Pharmaceutical as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in the stock. Parallel Advisors LLC raised its holdings in Ultragenyx Pharmaceutical by 778.4% during the first quarter. Parallel Advisors LLC now owns 1,625 shares of the biopharmaceutical company’s stock worth $34,000 after purchasing an additional 1,440 shares in the last quarter. Leonteq Securities AG boosted its holdings in shares of Ultragenyx Pharmaceutical by 288.5% in the 1st quarter. Leonteq Securities AG now owns 1,795 shares of the biopharmaceutical company’s stock valued at $38,000 after buying an additional 1,333 shares in the last quarter. Versant Capital Management Inc boosted its holdings in shares of Ultragenyx Pharmaceutical by 662.9% in the 2nd quarter. Versant Capital Management Inc now owns 1,152 shares of the biopharmaceutical company’s stock valued at $38,000 after buying an additional 1,001 shares in the last quarter. Danske Bank A S purchased a new position in shares of Ultragenyx Pharmaceutical in the 3rd quarter valued at $39,000. Finally, EverSource Wealth Advisors LLC grew its position in shares of Ultragenyx Pharmaceutical by 573.0% in the 1st quarter. EverSource Wealth Advisors LLC now owns 2,167 shares of the biopharmaceutical company’s stock valued at $45,000 after buying an additional 1,845 shares during the last quarter. 97.67% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Ultragenyx Pharmaceutical

In other news, Director Corazon (Corsee) D. Sanders sold 2,000 shares of the company’s stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $25.05, for a total value of $50,100.00. Following the completion of the sale, the director directly owned 21,095 shares of the company’s stock, valued at approximately $528,429.75. This represents a 8.66% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Howard Horn sold 4,653 shares of the stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $23.77, for a total transaction of $110,601.81. Following the sale, the chief financial officer owned 105,689 shares of the company’s stock, valued at $2,512,227.53. This trade represents a 4.22% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 8,552 shares of company stock worth $207,455. 5.20% of the stock is owned by company insiders.

Ultragenyx Pharmaceutical Price Performance

Shares of Ultragenyx Pharmaceutical stock opened at $26.44 on Thursday. The firm’s fifty day simple moving average is $28.61 and its 200-day simple moving average is $25.01. Ultragenyx Pharmaceutical Inc. has a 12 month low of $18.29 and a 12 month high of $39.89. The stock has a market capitalization of $2.61 billion, a price-to-earnings ratio of -4.53 and a beta of 0.35.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported ($0.90) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.22) by $0.32. Ultragenyx Pharmaceutical had a negative net margin of 81.79% and a negative return on equity of 1,024.42%. The firm had revenue of $214.00 million during the quarter, compared to analysts’ expectations of $183.08 million. During the same quarter in the prior year, the business earned ($1.17) EPS. Ultragenyx Pharmaceutical’s quarterly revenue was up 28.5% compared to the same quarter last year. Analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -3.99 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the stock. Royal Bank Of Canada boosted their price target on shares of Ultragenyx Pharmaceutical from $35.00 to $40.00 and gave the company an “outperform” rating in a research report on Tuesday, July 7th. Wells Fargo & Company raised their price objective on Ultragenyx Pharmaceutical from $45.00 to $46.00 and gave the stock an “overweight” rating in a report on Thursday, August 20th. Canaccord Genuity Group lifted their target price on Ultragenyx Pharmaceutical from $81.00 to $83.00 and gave the stock a “buy” rating in a research report on Thursday, August 20th. JPMorgan Chase & Co. boosted their target price on Ultragenyx Pharmaceutical from $75.00 to $80.00 and gave the company an “overweight” rating in a report on Tuesday. Finally, Barclays reduced their target price on Ultragenyx Pharmaceutical from $44.00 to $43.00 and set an “overweight” rating for the company in a report on Wednesday, April 29th. One analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $59.22.

Ultragenyx Pharmaceutical Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.